Brisbane, Australia-based AnteoTech, has successfully developed proof-of-concept covid-19 antigen and influenza A and B point-of-care lateral flow tests that can detect the presence of SARS-Cov-2 and influenza in less than 15 minutes.
The tests utilize AnteoTech’s patented AnteoBind activated europium technology and provide significantly higher sensitivity than that offered by currently available covid-19 tests. AnteoTech intends for the tests to be combined into a single multiplex test platform and be available in as little as 6 to 9 months following clinical trials and regulatory approvals.
AnteoTech is currently looking to build strategic partnerships with medical device manufacturers to expedite commercialization. Once deployed, the portable test could significantly reduce covid-19 spread by enabling detection and quarantine of infected individuals before symptoms develop.
“The development of this new platform marks a critical step in our collective journey to halt the spread of covid-19,” says Derek Thomson, CEO of AnteoTech. “By leveraging many years of expert insight in the form of our AnteoBind europium nanoparticle technology and applying it to this unique challenge, we’re enabling detection of the lower viral particle levels seen in earlier stages of covid-19 infection—levels which aren’t detectable with current gold-based diagnostics. As a result, we’re opening the possibility for better clinical decision-making and earlier direction of patients into quarantine to curtail disease spread.”
For more information, visit AnteoTech.
Featured image: Workflow for the AnteoTech COVID-19 antigen/Flu A&B multiplex test. Courtesy AnteoTech.
